Specify a stock or a cryptocurrency in the search bar to get a summary
Centogene B V
CNTGCentogene N.V., together with its subsidiaries, engages in the research and development of products for human genetics in Europe, the Middle East, North America, Latin America, and the Asia Pacific. It provides data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It operates through two segments: Pharmaceutical and Diagnostics. The company provides target and drug screening, clinical development, market access and expansion, as well as CENTOGENE Biodatabank licenses and insight report services. In addition, it offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany. Address: Am Strande 7, Rostock, Germany, 18055
Analytics
WallStreet Target Price
1.51 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CNTG
Dividend Analytics CNTG
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CNTG
Stock Valuation CNTG
Financials CNTG
Results | 2019 | Dynamics |